cor2ed
engage checkpoint medical linkedin twitter
bg

TRK fusion-positive cancer poster tour at ESMO 2022

TRK fusion-positive cancer poster tour at ESMO 2022

Prof. David Hong

NTRK CONNECT partnered with NTRKers on a poster tour at ESMO 2022. Led by Prof. David Hong, the tour provided patients and caregivers an opportunity to better understand the latest TRK fusion-positive cancer data, with a particular emphasis on lung cancer.

 

Video summaries of 2 abstracts from ESMO 2022 and 1 abstract from WCLC 2022 are available to view now.

 

 

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

preview next

Poster 1: Dufresne A. et al (ESMO 2022)

time | open 1 min | Oct 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Poster 2: McDermott R. et al (ESMO 2022)

time | open 2 min | Oct 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Poster 3: Moreno V. et al (WCLC 2022)

time | open 2 min | Oct 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

 

 

The three posters covered are:

  • Poster 1 - Larotracking - Real life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program (Dufresne A. et al)
  • Poster 2 - Efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase fusion cancer with an extended follow-up (McDermott R. et al)
  • Poster 3 - Extended follow-up of efficacy and safety of larotrectinib in patients with TRK fusion lung cancer (Moreno V. et al)

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.

Other programmes of interest